Download MendeleyDiscovery of a Novel Mutant-Selective Epidermal Growth Factor Receptor Inhibitor Using an In Silico Enabled Drug Discovery Platform.
Igawa, H., Konst, Z.A., Therrien, E., Shelley, M., Koldso, H., Bos, P.H., Negri, A., Verras, A., Guo, J., Dahlgren, M.K., Levinson, A., Parr, B.T., Kurhade, S.E., Latthe, P., Shetty, R., Santhanakrishnan, S., Amberg-Johnson, K., Futran, A.S., Atsriku, C., Pelletier, R.D., Liu, Z., Bell, J.A., Bhat, S., Svensson, M., Gerasyuto, A.I.(2024) J Med Chem 67: 21811-21840
- PubMed: 39666597
- DOI: https://doi.org/10.1021/acs.jmedchem.4c01405
- Primary Citation of Related Structures:
9D3V, 9D3W - PubMed Abstract:
Despite the success of first, second, and third generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for non-small cell lung cancer with classical EGFR mutations (L858R or Exon 19 deletions), disease progression occurs due to the acquisition of T790M and C797S resistance. Herein, we report a physics-based computationally driven lead identification approach that identified structurally unique imidazo[3.2- b ]pyrazoles as reversible and wild-type-sparing EGFR TKIs of classical mutations bearing both T790M and C797S. During profiling of imidazo[3.2- b ]pyrazoles, we elucidated the bioactivation mechanism causing CYP3A4/5 time-dependent inhibition (TDI) and found key modifications to mitigate the TDI. Compound 31 inhibited EGFR L858R/T790M/C797S in biochemical assays with a K i = 2.1 nM and EGFR del19/T790M/C797S in a Ba/F3 cellular assay with an IC 50 = 56.9 nM. The deuterated analogue of 31 ( 38 ) demonstrated dose-dependent tumor growth inhibition in a Ba/F3 EGFR del19/T790M/C797S CDX model by 47% at 50 mg/kg BID and 92% at 100 mg/kg BID.
- Schrödinger Inc., New York, New York 10036, United States.
Organizational Affiliation:
